Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience

Date
2017
Author
Karadogan, I.
Sonmez, M.
Gulbas, Z.
Tekgunduz, E.
Kaya, A. H.
Ozbalak, M.
Kaynar, L.
Yildirim, R.
Arat, M.
Tastemir, N.
Bekoz, H.
Karadurmus, N.
Paydas, S.
Turker, A.
Toptas, T.
Tuglular, T. Firatli
Ferhanoglu, B.
Demirkol, O.
Demirkurek, H. C.
Yilmaz, M.
Toprak, S. K.
Koseoglu, F. D.
Demirkaya, M.
Barista, I.
Hacioglu, S. Kabukcu
Dogu, M. H.
Ozcan, M.
Yuksel, M. Kurt
Turgut, M.
Abali, H.
Ozkocaman, V.
Tanrikulu, F. Pepedil
Metadata
Show full item record
Abstract
Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile.
URI
http://hdl.handle.net/20.500.12627/30315
https://doi.org/10.1093/annonc/mdx341
Collections